Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Typology of Ohio, USA, tree farmers based upon forestry outreach needs.

Starr SE, McConnell TE, Bruskotter JS, Williams RA.

Environ Manage. 2015 Feb;55(2):308-20. doi: 10.1007/s00267-014-0382-z. Epub 2014 Oct 14.

PMID:
25312296
2.

Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children.

Saitoh A, Powell CA, Fenton T, Douglas SD, Starr SE, Fletcher CV, Spector SA.

J Infect Dis. 2004 Apr 1;189(7):1216-20. Epub 2004 Mar 12.

PMID:
15031790
3.

Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy.

Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV.

Antimicrob Agents Chemother. 2004 Mar;48(3):979-84.

4.

Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children.

Starr SE, McFarland EJ, Muresan P, Fenton T, Pitt J, Douglas SD, Deveikis A, Levin MJ, Rathore MH; PACTG 299 Study Team.

AIDS. 2003 Oct 17;17(15):2181-9.

PMID:
14523275
5.

Increased proliferation within T lymphocyte subsets of HIV-infected adolescents.

Starr SE, Sarr M, Campbell DE, Wilson CM, Douglas SD.

AIDS Res Hum Retroviruses. 2002 Nov 20;18(17):1301-10.

PMID:
12487818
6.

Efavirenz liquid formulation in human immunodeficiency virus-infected children.

Starr SE, Fletcher CV, Spector SA, Brundage RC, Yong FH, Douglas SD, Flynn PM, Kline MW; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group.

Pediatr Infect Dis J. 2002 Jul;21(7):659-63.

PMID:
12237599
7.

Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA.

J Infect Dis. 2002 May 15;185(10):1409-16. Epub 2002 Apr 30.

PMID:
11992275
8.

HIV-1 infection of placental cord blood monocyte-derived dendritic cells.

Folcik RM, Merrill JD, Li Y, Guo CJ, Douglas SD, Starr SE, Ho WZ.

J Hematother Stem Cell Res. 2001 Oct;10(5):609-20.

9.

Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents.

Douglas SD, Durako SJ, Tustin NB, Houser J, Muenz L, Starr SE, Wilson C; Adolescent Medicine HIV/AIDS Research Network.

AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):543-52.

PMID:
11350668
10.

Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.

Spector SA, Hsia K, Yong FH, Cabral S, Fenton T, Fletcher CV, McNamara J, Mofenson LM, Starr SE.

J Infect Dis. 2000 Dec;182(6):1769-73. Epub 2000 Oct 26.

PMID:
11069252
11.

Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells.

Sullivan KE, Cutilli J, Piliero LM, Ghavimi-Alagha D, Starr SE, Campbell DE, Douglas SD.

Clin Diagn Lab Immunol. 2000 Nov;7(6):920-4.

12.

T-lymphocyte subsets in HIV-infected and high-risk HIV-uninfected adolescents: retention of naive T lymphocytes in HIV-infected adolescents. The Adolescent Medicine HIV/AIDS Research Network.

Douglas SD, Rudy B, Muenz L, Starr SE, Campbell DE, Wilson C, Holland C, Crowley-Nowick P, Vermund SH.

Arch Pediatr Adolesc Med. 2000 Apr;154(4):375-80.

PMID:
10768676
14.

Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).

Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, Burchett S.

J Infect Dis. 2000 Feb;181(2):548-54.

PMID:
10669338
15.

Rapid method for determining the rate of DNA synthesis and cellular proliferation.

Nissim I, Starr SE, Sullivan KE, Campbell DE, Douglas SD, Daikhin Y, Yudkoff M.

Anal Biochem. 2000 Feb 15;278(2):198-205.

PMID:
10660463
16.

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.

N Engl J Med. 1999 Dec 16;341(25):1874-81.

17.

Human immunodeficiency virus infection of human placental cord blood CD34+AC133+ stem cells and their progeny.

Hariharan D, Li Y, Campbell DE, Douglas SD, Starr SE, Ho W.

AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1545-52.

PMID:
10580405
18.

Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.

Ziegner U, Campbell D, Weinhold K, Frank I, Rutstein R, Starr SE.

Clin Diagn Lab Immunol. 1999 Sep;6(5):718-24.

20.

Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission.

Wasik TJ, Bratosiewicz J, Wierzbicki A, Whiteman VE, Rutstein RR, Starr SE, Douglas SD, Kaufman D, Sison AV, Polansky M, Lischner HW, Kozbor D.

J Immunol. 1999 Apr 1;162(7):4355-64.

21.

Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments.

Ho WZ, Lai JP, Bouhamdan M, Duan L, Pomerantz RJ, Starr SE.

AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1573-80.

PMID:
9840290
22.

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.

Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S.

Pediatr Infect Dis J. 1998 Mar;17(3):200-6.

PMID:
9535246
23.

Immunizing the HIV-infected child.

Rutstein RM, Starr SE.

AIDS Patient Care STDS. 1997 Jun;11(3):149-60. No abstract available.

PMID:
11361788
24.
25.
26.

Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ.

J Infect Dis. 1996 Dec;174(6):1162-7.

PMID:
8940204
27.

Novel mechanism of immunosuppression after measles.

Starr SE.

Lancet. 1996 Nov 9;348(9037):1257-8. No abstract available.

PMID:
8909375
28.

Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.

Wang JB, Adler SP, Hempfling S, Burke RL, Duliège AM, Starr SE, Plotkin SA.

J Infect Dis. 1996 Aug;174(2):387-92.

PMID:
8699071
29.

Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.

Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE.

J Infect Dis. 1996 Mar;173(3):731-4. Erratum in: J Infect Dis 1996 Jun;173(6):1529.

PMID:
8627041
30.

Resistance to antivirals.

Laufer DS, Starr SE.

Pediatr Clin North Am. 1995 Jun;42(3):583-99. Review.

PMID:
7761142
31.

Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine.

Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE.

Clin Infect Dis. 1995 Feb;20(2):316-9.

PMID:
7742436
32.

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM.

J Infect Dis. 1995 Jan;171(1):26-32. Erratum in: J Infect Dis 1995 Apr;171(4):1080.

PMID:
7798679
33.

Varicella vaccine for healthy children.

Watson BA, Starr SE.

Lancet. 1994 Apr 16;343(8903):928-9. No abstract available.

PMID:
7909003
34.

Impaired interleukin 12 production in human immunodeficiency virus-infected patients.

Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, Sennelier J, Trinchieri G.

J Exp Med. 1994 Apr 1;179(4):1361-6.

35.

Cytofluorographic analysis of effects of interferons on expression of human cytomegalovirus proteins.

Torigoe S, Campbell DE, Torigoe F, Michelson S, Starr SE.

J Virol Methods. 1993 Dec 15;45(2):219-28.

PMID:
7509340
36.

Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.

Chehimi J, Valiante NM, D'Andrea A, Rengaraju M, Rosado Z, Kobayashi M, Perussia B, Wolf SF, Starr SE, Trinchieri G.

Eur J Immunol. 1993 Aug;23(8):1826-30.

PMID:
8102101
37.

CD4-independent infection of human peripheral blood dendritic cells with isolates of human immunodeficiency virus type 1.

Chehimi J, Prakash K, Shanmugam V, Collman R, Jackson SJ, Bandyopadhyay S, Starr SE.

J Gen Virol. 1993 Jul;74 ( Pt 7):1277-85.

PMID:
8336119
38.

Mycobacterium avium intracellulare complex infection in HIV-infected children.

Rutstein RM, Cobb P, McGowan KL, Pinto-Martin J, Starr SE.

AIDS. 1993 Apr;7(4):507-12.

PMID:
8099487
39.

Modified chickenpox in children immunized with the Oka/Merck varicella vaccine.

Watson BM, Piercy SA, Plotkin SA, Starr SE.

Pediatrics. 1993 Jan;91(1):17-22. Review.

PMID:
8416499
40.

Morphological and functional differences between HLA-DR+ peripheral blood dendritic cells and HLA-DR+ IFN-alpha producing cells.

Starr SE, Bandyopadhyay S, Shanmugam V, Hassan N, Douglas S, Jackson SJ, Trinchieri G, Chehimi J.

Adv Exp Med Biol. 1993;329:173-8. No abstract available.

PMID:
8397473
41.

In-vitro infection of peripheral blood dendritic cells with human immunodeficiency virus-1 causes impairment of accessory functions.

Chehimi J, Prakash K, Shanmugam V, Jackson SJ, Bandyopadhyay S, Starr SE.

Adv Exp Med Biol. 1993;329:521-6. No abstract available.

PMID:
8379420
42.

Cytomegalovirus vaccines: current status.

Starr SE.

Infect Agents Dis. 1992 Jun;1(3):146-8. Review.

PMID:
1365538
43.

Varicella in children receiving steroids for asthma: risks and management.

Starr SE.

Pediatr Infect Dis J. 1992 May;11(5):419-20. No abstract available.

PMID:
1630872
44.

Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.

Chehimi J, Starr SE, Frank I, Rengaraju M, Jackson SJ, Llanes C, Kobayashi M, Perussia B, Young D, Nickbarg E, et al.

J Exp Med. 1992 Mar 1;175(3):789-96.

45.
46.

The status of cytomegalovirus vaccine.

Starr SE, Friedman HM, Plotkin SA.

Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S964-5. Review.

PMID:
1664136
47.

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies.

Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ, Watson BA, Starr SE, Plotkin SA.

Vaccine. 1991 Sep;9(9):643-7.

PMID:
1659052
48.
49.

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.

Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C.

Ann Intern Med. 1991 Apr 1;114(7):525-31.

PMID:
1848053
50.

In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates.

Chehimi J, Bandyopadhyay S, Prakash K, Perussia B, Hassan NF, Kawashima H, Campbell D, Kornbluth J, Starr SE.

J Virol. 1991 Apr;65(4):1812-22.

Supplemental Content

Loading ...
Support Center